Supply of Diphenhydramine Hydrochloride Injection to USNS GUAM, Okinawa

The contract obligates the supply and delivery of FDA-compliant Diphenhydramine Hydrochloride Injection, identified by NSN 6505016490647 and NDC 76045-0102-10, in 1.000 box units to USNS GUAM located in Okinawa, Japan. The product must meet all applicable FDA standards and be packaged and labeled in accordance with military and regulatory requirements for pharmaceuticals in federal supply chains. Delivery is structured under FOB Destination terms, meaning the vendor assumes all risks and costs until the goods are physically received at the designated military vessel location in Okinawa, ensuring accountability for safe transit through international shipping channels. The procurement is administered by the Defense Logistics Agency under the Department of Defense, classified under NAICS code 325412 for pharmaceutical and biological product manufacturing. The contract was posted on August 5, 2026, and is designated as a subcontract, though no specific set-aside provisions apply. The delivery window and exact receipt timeline are not detailed, but the FOB Destination condition mandates precise coordination with the vessel’s operational schedule. All documentation must align with defense logistics protocols and pharmaceutical handling standards to ensure compatibility with US Navy medical protocols on board.